Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Examining tDCS Effect on Cannabis Use Disorder in Patients With Schizophrenia

NCT: NCT04871048 · RECRUITING

NCT IDNCT04871048
StatusRECRUITING
Start Date2023-02-15
Completion2030-06-30

Brief Summary

Cannabis use disorder is a frequent comorbidity of schizophrenia, associated with increased symptoms and less adherence to therapy. Validated care has limited effectiveness in this population and development of new management strategies seems necessary. Transcranial direct current stimulation (tDCS) has shown beneficial effects in both schizophrenia, substance use disorder and, in a less extent, in nicotine addiction in schizophrenic subjects. It is interesting to test if that 10 sessions of anodal stimulation of the right dorsolateral prefrontal cortex (DLPFC) and cathodal stimulation of the medial prefrontal cortex (MPFC) (by increasing control and modulating reward system), will reduce, in 110 schizophrenic subjects, cannabis consumption, and secondly craving, addiction severity, schizophrenic symptoms and improve global functioning. It is possible that these clinical effects will be associated with changes in certain cognitive functions and cerebral connectivity.

Frequently Asked Questions

What is Examining tDCS Effect on Cannabis Use Disorder in Patients With Schizophrenia?

Examining tDCS Effect on Cannabis Use Disorder in Patients With Schizophrenia is a clinical trial registered under NCT04871048. Current status: RECRUITING.

What is the status of NCT04871048?

The current status of NCT04871048 (Examining tDCS Effect on Cannabis Use Disorder in Patients With Schizophrenia) is: RECRUITING.

When did Examining tDCS Effect on Cannabis Use Disorder in Patients With Schizophrenia start?

Examining tDCS Effect on Cannabis Use Disorder in Patients With Schizophrenia started on 2023-02-15.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.